The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.
Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.
The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback